BioCentury | Sep 25, 2020
Finance

Palladio seeks to position Orphan kidney therapy as safer alternative with $20 million series B

...trial that will help determine whether lixivaptan represents a safer alternative to Jinarc tolvaptan from Otsuka Pharmaceutical...
BioCentury | Sep 4, 2020
Product Development

Akebia’s prospects dim after safety readout in non-dialysis CKD patients

...next year. It will work with partner Otsuka Pharmaceutical...
BioCentury | May 6, 2020
Product Development

May 5 Quick Takes: Data propel Adverum, TG, Akebia stocks; plus Tolmar, SRI-Exscientia, Sino-GeoVax

...to seek approval of the oral HIF-PH inhibitor, which is partnered in different territories with Otsuka Pharmaceutical...
BioCentury | Apr 21, 2020
Product Development

April 20 Quick Takes: Top-line data for BMS, Idorsia and Ascendis; plus Otsuka-Esperion, Regeneron and more

...14%) to CHF30.22 on the Swiss Exchange Monday. Otsuka gains Japan rights to Esperion drugs Otsuka Pharmaceutical...
...VP30 - Ebola virus VP30 BioCentury Staff bempedoic acid/ezetimibe Regeneron Pharmaceuticals Inc. Galapagos N.V. Bristol Myers Squibb Co. Idorsia Ltd. Ascendis Pharma A/S Otsuka Pharmaceutical...
BioCentury | Mar 27, 2020
Product Development

March 26 Quick Takes: Pear’s digital therapeutic approved for insomnia; plus Medimetriks-Otsuka, Merck KGaA, Jazz, Roche, EpiVax

...in the U.S. after reporting top-line results from two Phase III Japan trials conducted by Otsuka Pharmaceutical...
...Bacterial UDP-3-O-[3-hydroxymyristoyl] N-acetylglucosamine deacetylase PDE-4 - Phosphodiesterase-4 Hongjiang Li, Staff Writer tepotinib (MSC2156119J) JZP-258 Pear Therapeutics Inc. Medimetriks Pharmaceuticals Inc. Otsuka Pharmaceutical...
BioCentury | Mar 10, 2020
Finance

LSP to deploy $600M fund to retain larger stakes in early-stage European biotechs

...fund include two disclosed strategics, return investor Bristol Myers Squibb Co. (NYSE:BMY) and new investor Otsuka Pharmaceutical...
BioCentury | Jan 7, 2020
Company News

In deal with Taiho and Astex, Merck gains another K-Ras program

...$50 million up front to Taiho Pharmaceutical Co. Ltd. and the Astex Pharmaceuticals subsidiary of Otsuka Pharmaceutical...
...death 1 Paul Bonanos, Associate Editor Merck & Co. Inc. Taiho Pharmaceutical Co. Ltd. Astex Pharmaceuticals Inc. Otsuka Holdings Co. Ltd. Otsuka Pharmaceutical...
BioCentury | Nov 19, 2019
Company News

Alkermes expands CNS pipeline with Rodin acquisition

...Alkermes sees Rodin's programs as complementary to its neuropsychiatry portfolio, which includes schizophrenia drug Aristada aripiprazole...
BioCentury | Nov 14, 2019
Company News

Management tracks: Longtime Abbott CEO resigning; plus Otsuka, Bavarian Nordic, Progenics and Rakuten

...joined the company in 1996, will become CEO and has been elected to the board. Otsuka Pharmaceutical...
...has no plans at this time to appoint his successor. OPDC is a subsidiary of Otsuka Pharmaceutical...
BioCentury | Oct 23, 2019
Company News

With MS approval looming, Alkermes restructures to seek sustainable profits

...growth drivers are Vivitrol naltrexone, which is approved for opioid or alcohol dependence, and Aristada aripiprazole...
Items per page:
1 - 10 of 1021